Retrieve available abstracts of 30 articles: HTML format
Single Articles
May 2025
HAMZAOUI H, Shaum A, Cherkaoui I, Moussa LA, et al Assessment of Pharmacovigilance Across University Hospitals in Morocco.
Drug Saf. 2025;48:527-539. PubMedAbstract available
March 2025
NAMBASA VP, Gunter HM, Adeyemo MB, Bhawaneedin NY, et al Empowering African Expertise: Enhancing Safety Data Integration and Signal
Detection for COVID-19 Vaccines Through the African Union Smart Safety
Surveillance Joint Signal Management Group.
Drug Saf. 2025;48:233-249. PubMedAbstract available
BOULEFAA D, Bagheri H, Salvo F, Rabier MB, et al Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A
Disproportionality Analysis Study on French Pharmacovigilance Database.
Drug Saf. 2025;48:251-263. PubMedAbstract available
November 2024
MORCIANO C, Massari M, Cutillo M, Belleudi V, et al Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case
Series Study.
Drug Saf. 2024;47:1157-1169. PubMedAbstract available
October 2024
CIAPPONI A, Berrueta M, Argento FJ, Ballivian J, et al Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living
Systematic Review and Meta-analysis.
Drug Saf. 2024;47:991-1010. PubMedAbstract available
YAN VKC, Yang Y, Wan EYF, Lai FTT, et al Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial
Emulation Study.
Drug Saf. 2024;47:1025-1037. PubMedAbstract available
BELLITTO C, Luxi N, Ciccimarra F, L'Abbate L, et al What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results
from the European "Covid Vaccine Monitor" Active Surveillance Study.
Drug Saf. 2024;47:1011-1023. PubMedAbstract available
September 2024
WYSZYNSKI DF, Demetriou L, Renz C, Aliabadi S, et al Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug
Pregnancy Registry.
Drug Saf. 2024;47:843-851. PubMedAbstract available
August 2024
GORDILLO-MARANON M, Szmigiel A, Yalmanova V, Caplanusi I, et al COVID-19 Vaccines and Heavy Menstrual Bleeding: The Impact of Media Attention on
Reporting to EudraVigilance.
Drug Saf. 2024;47:783-798. PubMedAbstract available
July 2024
GORDILLO-MARANON M, Candore G, Hedenmalm K, Browne K, et al Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During
Mass Vaccination.
Drug Saf. 2024;47:607-615. PubMedAbstract available
June 2024
DE LA CUEVA IS, Gerber JE, Hastie A, Brotons C, et al Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza
Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season.
Drug Saf. 2024 Jun 29. doi: 10.1007/s40264-024-01456. PubMedAbstract available
May 2024
CAPLANUSI I, Szmigiel A, van der Elst M, Schougaard Christiansen ML, et al The Role of the European Medicines Agency in the Safety Monitoring of COVID-19
Vaccines and Future Directions in Enhancing Vaccine Safety Globally.
Drug Saf. 2024;47:405-418. PubMedAbstract available
March 2024
DOS SANTOS G, Devadiga R, Kim CS, Bang J, et al An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety
Surveillance Study Conducted in South Korea (2014-2022) Following the
Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine
(Fluarix Tetra) for Subjects Aged
Drug Saf. 2024 Mar 14. doi: 10.1007/s40264-024-01395. PubMedAbstract available
WYSZYNSKI DF, Papageorghiou AT, Renz C, Metz TD, et al The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol
Considerations.
Drug Saf. 2024;47:195-204. PubMedAbstract available
February 2024
MORO PL, Ennulat C, Brown H, Woody G, et al Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza
Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
Drug Saf. 2024 Feb 27. doi: 10.1007/s40264-024-01406. PubMedAbstract available
QIN SX, Cheng FWT, Kwok WC, Fung LWY, et al Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA
COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based
Study.
Drug Saf. 2024;47:135-146. PubMedAbstract available
DONG G, Bate A, Haguinet F, Westman G, et al Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A
Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural
Language Processing.
Drug Saf. 2024;47:173-182. PubMedAbstract available
December 2023
DE GERMAY S, Singier A, Salvo F, Pariente A, et al Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in
France.
Drug Saf. 2023;46:1381-1389. PubMedAbstract available
November 2023
MICALLEF B, Dogne JM, Sultana J, Straus SMJM, et al An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on
Masking Signal Detection in EudraVigilance.
Drug Saf. 2023;46:1089-1103. PubMedAbstract available
October 2023
SLINGERLAND P, van Hunsel FPAM, Lieber T, van Balveren L, et al The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of
Adverse Events Following Seasonal Influenza Vaccination in the Netherlands.
Drug Saf. 2023 Oct 26. doi: 10.1007/s40264-023-01356. PubMedAbstract available
September 2023
WALTON M, Pletzer V, Teunissen T, Lumley T, et al Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in
Aotearoa New Zealand.
Drug Saf. 2023;46:867-879. PubMedAbstract available
June 2023
KAUR U, Fatima Z, Maheshwari K, Sahni V, et al Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results
from a Prospective Observational Study in Priority Vaccinated Groups in North
India.
Drug Saf. 2023;46:553-563. PubMedAbstract available
AHMADIZAR F, Luxi N, Raethke M, Schmikli S, et al Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the
European Surveillance Systems and Pivotal Clinical Trials.
Drug Saf. 2023;46:575-585. PubMedAbstract available
May 2023
KRALOVA K, Wilson CA, Richebourg N, D'souza J, et al Quality of MedDRA((R)) Coding in a Sample of COVID-19 Vaccine Medication Error
Data.
Drug Saf. 2023;46:501-507. PubMedAbstract available
April 2023
BAUCHAU V, Davis K, Frise S, Jouquelet-Royer C, et al Real-World Monitoring of COVID-19 Vaccines: An Industry Expert View on the
Successes, Challenges, and Future Opportunities.
Drug Saf. 2023;46:327-333. PubMedAbstract available
RAETHKE M, van Hunsel F, Thurin NH, Dureau-Pournin C, et al Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven
European Countries: Pooled Results on First Dose.
Drug Saf. 2023;46:391-404. PubMedAbstract available
OGAR CK, Quick J, Gilbert HN, Vreman RA, et al Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that
Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A
Mixed Methods Study.
Drug Saf. 2023;46:357-370. PubMedAbstract available
March 2023
KALKNER KM, Sundstrom A, Nurminen ML, Larsson M, et al Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical
Products Agency.
Drug Saf. 2023;46:319-321. PubMed
WYSZYNSKI DF, Bhattacharya M, Martinez-Perez O, Scialli AR, et al The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER):
Protocol and Methodological Considerations.
Drug Saf. 2023;46:297-308. PubMedAbstract available
ZAPATA-CACHAFEIRO M, Prieto-Campo A, Portela-Romero M, Carracedo-Martinez E, et al Effect of Previous Anticoagulant Treatment on Risk of COVID-19.
Drug Saf. 2023;46:273-281. PubMedAbstract available